文献速递淋巴瘤

评估皮下利妥昔单抗一线治疗低肿瘤负荷滤泡性淋巴瘤的随机III期试验:LYSA研究结果

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.
PubMed 文献 · J Clin Oncol · 2023-04-18

本研究为随机III期试验,纳入202例组织学确诊的CD20+低肿瘤负荷滤泡性淋巴瘤患者,比较静脉利妥昔单抗诱导后短程皮下维持方案(实验组)与标准静脉方案(对照组)的疗效。主要终点无进展生存期达到:实验组4年PFS为58.1%,对照组为41.2%(HR 0.585,P=0.0076),完全缓解率分别为59.0%和36.3%(P=0.001),至下次治疗时间和总生存期无显著差异。

要点

  • 实验组4年无进展生存期58.1%,对照组41.2%,风险比0.585(95%CI 0.393-0.871),P=0.0076,差异有统计学意义。
  • 实验组完全缓解率59.0%(95%CI 48.7-68.7),对照组36.3%(95%CI 27.0-46.4),P=0.001。
  • 至下次治疗时间和总生存期两组无显著差异;治疗开始后前3个月高利妥昔单抗暴露与更高的完全缓解、无进展生存和至下次治疗时间独立相关。

核心结论

  • 皮下利妥昔单抗诱导后短程维持治疗可改善低肿瘤负荷滤泡性淋巴瘤患者的无进展生存期。
  • 治疗开始后前3个月的高利妥昔单抗暴露是唯一影响患者结局的参数。

研究设计与样本

  • 随机III期试验,纳入202例组织学确诊的CD20+低肿瘤负荷滤泡性淋巴瘤患者。
  • 实验组100例:第1天静脉利妥昔单抗375 mg/m2,第8、15、22天皮下利妥昔单抗总剂量1,400 mg,第3、5、7、9个月维持治疗。
  • 对照组102例:第1、8、15、22天静脉利妥昔单抗375 mg/m2。
  • 主要终点为无进展生存期;次要终点包括安全性、总缓解率、至下次治疗时间和总生存期。

主要发现

  • 4年无进展生存率:实验组58.1%(95%CI 47.5-67.4),对照组41.2%(95%CI 30.6-51.6),风险比0.585(95%CI 0.393-0.871),P=0.0076。
  • 完全缓解率:实验组59.0%(95%CI 48.7-68.7),对照组36.3%(95%CI 27.0-46.4),P=0.001。
  • 至下次治疗时间和总生存期两组无显著差异。
  • 完全缓解与更长的无进展生存期和至下次治疗时间相关。
  • 治疗开始后前3个月高利妥昔单抗暴露与更高的完全缓解、无进展生存和至下次治疗时间独立相关。

关键数值与推荐

  • 主要终点达到:4年无进展生存率实验组58.1%(95%CI 47.5-67.4)vs 对照组41.2%(95%CI 30.6-51.6)(风险比0.585,95%CI 0.393-0.871,P=0.0076)。
  • 完全缓解率实验组59.0%(95%CI 48.7-68.7)vs 对照组36.3%(95%CI 27.0-46.4)(P=0.001)。

临床怎么用

  • 对于低肿瘤负荷滤泡性淋巴瘤患者,皮下利妥昔单抗诱导后短程维持治疗可考虑用于改善无进展生存期。
  • 治疗开始后前3个月的高利妥昔单抗暴露与更好的完全缓解、无进展生存和至下次治疗时间独立相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Rituximab improves progression-free survival (PFS) and time to next treatment (TTNT) when compared with the watch and wait strategy for patients with low-tumor burden follicular lymphoma (FL). Prolonged rituximab maintenance did not prolong TTNT, whereas it raises concerns about resources use and patient adhesion. Our aim was then to investigate the use of short rituximab maintenance using the subcutaneous (SC) route in patients with low-tumor burden FL. METHODS: Patients with histologically confirmed CD20+ low-tumor burden FL were randomly assigned to receive either rituximab, 375 mg/m2 once daily on D1, D8, D15, and D22, intravenous route (IV, control arm), or rituximab, 375 mg/m2, on day 1 (D1), IV followed by rituximab 1,400 mg total dose, SC once daily on D8, D15, and D22, with maintenance at months 3 (M3), M5, M7, and M9 (experimental arm). The primary end point was PFS. Secondary end points included safety, overall response rates, TTNT, and overall survival (OS). RESULTS: Two hundred two patients with low-tumor burden FL were randomly assigned to the experimental (n = 100) or control arm (n = 102). The primary end point was met: the 4-year PFS was 58.1% (95% CI, 47.5 to 67.4) and 41.2% (95% CI, 30.6 to 51.6) in experimental and control arms, respectively (hazard ratio, 0.585 [0.393 to 0.871]; P = .0076). Complete response (CR) rates were 59.0% (95% CI, 48.7 to 68.7) in the experimental arm and 36.3% (95% CI, 27.0 to 46.4) in the control arm (P = .001). TTNT and OS were not significantly different. CR was associated with longer PFS and TTNT. High rituximab exposure during the first three months was independently associated with higher CR, PFS, and TTNT. CONCLUSION: SC rituximab improves PFS for patients with low-tumor burden FL when used in induction followed by short maintenance. High rituximab exposure during the first 3 months after treatment initiation is, however, the only parameter influencing patient outcomes.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Cartron G, Bachy E, Tilly H, et al. Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study. J Clin Oncol. 2023. PMID: 37071836. doi:10.1200/JCO.22.02327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。